May 2, 2013 / 11:22 AM / in 5 years

Shire delivers Q1 earnings beat on strong product sales

LONDON, May 2 (Reuters) - British pharmaceutical firm Shire beat expectations with a 10 percent rise in first-quarter earnings on Thursday after a strong performance from its drugs that treat hyperactivity.

In the first set of results with new chief executive Flemming Ornskov at the helm, Shire posted non-GAAP earnings per ADS of $1.63, beating analyst forecasts of $1.59.

Revenue of $1,162 million was down 1 percent, falling short of the $1,221 million the market expected, as growth in product sales was offset by lower royalties, particularly for hyperactivity drug Adderall XR from Impax Laboratories Inc .

As well as treatments for hyperactivity, London-listed Shire focuses on niche rare disease areas.

The company said it was confident it would deliver earnings growth in line with market expectations for the full year.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below